NASDAQ: PTHLPheton Holdings Ltd Stock
$2.63-0.16 (-5.73%)
Updated Feb 14, 2025
PTHL Price
$2.63
Fair Value Price
N/A
Market Cap
$38.14M
52 Week Low
$2.35
52 Week High
$6.45
P/E
N/A
P/B
2,357.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
83.19
Operating Cash Flow
N/A
Beta
-0.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTHL Overview
Pheton Holdings Ltd, a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system is FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients. The company was founded in 1998 and is based in Beijing, China. Pheton Holdings Ltd operates as a subsidiary of ZJW (BVI) LTD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTHL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PTHL news, forecast changes, insider trades & much more!
PTHL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTHL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTHL is poor value based on its book value relative to its share price (2,357.94x), compared to the US Medical Devices industry average (4.36x)
P/B vs Industry Valuation
PTHL's short-term liabilities ($1.27M) exceed its short-term assets ($290.89k)
Short-term Liabilities Financials
PTHL's short-term assets ($290.89k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more PTHL due diligence checks available for Premium users.
Valuation
PTHL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2,357.94x
Industry
4.36x
PTHL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTHL's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$1.4M
Liabilities
$1.3M
Debt to equity
83.19
PTHL's short-term liabilities ($1.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTHL's short-term assets ($290.89k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTHL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PTHL vs Medical Device Stocks
Pheton Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.